PL3233108T3 - Kompozycje insuliny o szybkim działaniu - Google Patents

Kompozycje insuliny o szybkim działaniu

Info

Publication number
PL3233108T3
PL3233108T3 PL15817678T PL15817678T PL3233108T3 PL 3233108 T3 PL3233108 T3 PL 3233108T3 PL 15817678 T PL15817678 T PL 15817678T PL 15817678 T PL15817678 T PL 15817678T PL 3233108 T3 PL3233108 T3 PL 3233108T3
Authority
PL
Poland
Prior art keywords
rapid
acting insulin
insulin compositions
compositions
acting
Prior art date
Application number
PL15817678T
Other languages
English (en)
Polish (pl)
Inventor
Michael Patrick AKERS
Ranajoy Majumdar
Chi A. Nguyen
Chad D. Paavola
Virender Kumar Sarin
Nanette Elizabeth Schulte
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55066806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3233108(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL3233108T3 publication Critical patent/PL3233108T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL15817678T 2014-12-16 2015-12-09 Kompozycje insuliny o szybkim działaniu PL3233108T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462092407P 2014-12-16 2014-12-16
PCT/US2015/064744 WO2016100042A1 (en) 2014-12-16 2015-12-09 Rapid-acting insulin compositions
EP15817678.4A EP3233108B1 (en) 2014-12-16 2015-12-09 Rapid-acting insulin compositions

Publications (1)

Publication Number Publication Date
PL3233108T3 true PL3233108T3 (pl) 2022-06-20

Family

ID=55066806

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15817678T PL3233108T3 (pl) 2014-12-16 2015-12-09 Kompozycje insuliny o szybkim działaniu

Country Status (18)

Country Link
US (4) US9993555B2 (enExample)
EP (2) EP4108253A1 (enExample)
JP (5) JP6328855B2 (enExample)
AR (1) AR102869A1 (enExample)
CY (1) CY1125275T1 (enExample)
DK (1) DK3233108T3 (enExample)
ES (1) ES2911207T3 (enExample)
HR (1) HRP20220692T1 (enExample)
HU (1) HUE058764T2 (enExample)
LT (1) LT3233108T (enExample)
MA (1) MA41188B1 (enExample)
MD (1) MD3233108T2 (enExample)
PL (1) PL3233108T3 (enExample)
PT (1) PT3233108T (enExample)
RS (1) RS63174B1 (enExample)
SI (1) SI3233108T1 (enExample)
TW (1) TW201630622A (enExample)
WO (1) WO2016100042A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2910570T3 (en) 2008-03-18 2017-01-30 Novo Nordisk As Protease-stabilized acylated insulin analogues.
EP2919804B1 (fr) 2012-11-13 2018-01-31 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
AR102869A1 (es) * 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
WO2018060735A1 (en) * 2016-09-29 2018-04-05 Arecor Limited Novel formulations
TWI700091B (zh) 2016-12-16 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 含胰島素醫藥組成物
US20180236080A1 (en) * 2017-02-22 2018-08-23 Adocia Fast-acting insulin composition comprising a citric acid salt
MX2019011603A (es) * 2017-03-26 2021-08-16 Robyn Vivi Stafford Metodo de tratamiento de las condiciones de la piel de los parpados.
IL270975B2 (en) 2017-06-01 2024-02-01 Lilly Co Eli Fast-acting insulin preparations
CN112040928A (zh) * 2018-04-04 2020-12-04 艾瑞克有限公司 用于递送胰岛素化合物的医用输注泵系统
IL277721B2 (en) 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump system for the delivery of an insulin compound
CA3094304A1 (en) 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
EP3937920B1 (en) * 2019-03-14 2025-07-09 The Regents of the University of California Compositions comprising beta-hydroxybutyrate and citrate for supporting renal health
US10639328B1 (en) * 2019-03-27 2020-05-05 College Of William & Mary Compositions and methods for reducing hyperglycemia and treating diabetes
US10799564B1 (en) 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same
AU2020351154A1 (en) * 2019-09-17 2022-03-31 Cass Pharmaceuticals, Inc. Subcutaneously injectable insulin formulations and methods of administration
WO2021081404A1 (en) 2019-10-25 2021-04-29 Cercacor Laboratories, Inc. Indicator compounds, devices comprising indicator compounds, and methods of making and using the same
CN115916243A (zh) * 2020-03-02 2023-04-04 塞尔玛琳公司 含有速效胰岛素类似物的组合物
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK116527B (da) 1967-03-01 1970-01-19 Nordisk Insulinlab Fremgangsmåde til fremstilling af en hurtigtvirkende, holdbar, neutral opløsning af rent krystallinsk okseinsulin eller okseinsulin, der ved tilsætning af Zn er krystalliserbart i vand, eller blandinger af okseinsulin og insulin af anden oprindelse.
DE3064888D1 (en) 1979-04-30 1983-10-27 Hoechst Ag Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NO162160C (no) 1987-01-09 1989-11-15 Medi Cult As Serumfritt vekstmedium, samt anvendelse derav.
WO1988006599A1 (en) 1987-02-25 1988-09-07 Novo Industri A/S Novel insulin derivatives
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
US5716927A (en) 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
AUPO066096A0 (en) 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
EP1044016B1 (en) 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
WO2000043034A2 (en) 1999-01-26 2000-07-27 Eli Lilly And Company Monodisperse hexameric acylated insulin analog formulations
CN1284522C (zh) 1999-11-15 2006-11-15 哈纳曼阿迪，T.·甘加尔 用于静脉输注的葡萄糖和胰岛素液体组合物
JP4147234B2 (ja) 2004-09-27 2008-09-10 キヤノン株式会社 吐出用液体、吐出方法、カートリッジ及び吐出装置
US20020141946A1 (en) 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
ATE525083T1 (de) * 2003-11-13 2011-10-15 Novo Nordisk As Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US7279457B2 (en) 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2007041481A1 (en) 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
JP2009533471A (ja) 2006-04-12 2009-09-17 バイオデル， インコーポレイテッド 即効型および長時間作用型組合せインスリン製剤
US8084022B2 (en) 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
WO2008013955A2 (en) 2006-07-27 2008-01-31 Nektar Therapeutics Sustained release formulations for pulmonary delivery
CN101677947B (zh) * 2007-06-13 2013-07-17 诺沃-诺迪斯克有限公司 包含胰岛素衍生物的药物制剂
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
US20120094902A1 (en) 2009-03-27 2012-04-19 Adocia Fast-acting insulin formulation
MX2011012764A (es) 2009-06-26 2012-01-20 Novo Nordisk As Preparacion que comprende insulina, nicotinamida y un aminoacido.
WO2012006283A1 (en) 2010-07-07 2012-01-12 Biodel Inc. Compositions and methods for modulating the pharmacokinetics and pharmacodynamics of insulin
CN105797140B (zh) * 2011-06-17 2020-08-11 哈洛齐梅公司 乙酰透明质酸降解酶的稳定制剂
EP2720713A2 (en) 2011-06-17 2014-04-23 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
SI3130347T1 (sl) 2011-12-30 2020-02-28 Halozyme, Inc. Variante polipeptida PH20, formulacije in uporabe le-teh
US9399065B2 (en) * 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
US9381247B2 (en) 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
WO2013177565A1 (en) 2012-05-25 2013-11-28 Amylin Pharmaceuticals, Llc Insulin-pramlintide compositions and methods for making and using them
EP2919804B1 (fr) 2012-11-13 2018-01-31 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
US20150065423A1 (en) 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
CN106102763A (zh) 2014-01-13 2016-11-09 塞尔玛琳糖尿病有限责任公司 速效胰岛素制剂和药物递送系统
US20150273022A1 (en) 2014-02-10 2015-10-01 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
AR102869A1 (es) * 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول

Also Published As

Publication number Publication date
JP2025032126A (ja) 2025-03-11
US20220072105A1 (en) 2022-03-10
ES2911207T3 (es) 2022-05-18
US11872266B2 (en) 2024-01-16
AR102869A1 (es) 2017-03-29
HRP20220692T1 (hr) 2022-07-08
US11123406B2 (en) 2021-09-21
TW201630622A (zh) 2016-09-01
JP2018138578A (ja) 2018-09-06
DK3233108T3 (da) 2022-04-11
JP2023011641A (ja) 2023-01-24
JP7093669B2 (ja) 2022-06-30
US20240238382A1 (en) 2024-07-18
MA41188B1 (fr) 2022-08-31
PT3233108T (pt) 2022-05-05
LT3233108T (lt) 2022-05-10
EP3233108B1 (en) 2022-03-30
EP4108253A1 (en) 2022-12-28
JP6328855B2 (ja) 2018-05-23
WO2016100042A1 (en) 2016-06-23
SI3233108T1 (sl) 2022-05-31
JP7159277B2 (ja) 2022-10-24
CY1125275T1 (el) 2024-12-13
MA41188A (fr) 2017-10-24
US9993555B2 (en) 2018-06-12
US20160166695A1 (en) 2016-06-16
RS63174B1 (sr) 2022-05-31
HUE058764T2 (hu) 2022-09-28
US20190231851A1 (en) 2019-08-01
MD3233108T2 (ro) 2022-09-30
EP3233108A1 (en) 2017-10-25
JP2021073187A (ja) 2021-05-13
JP2018500314A (ja) 2018-01-11

Similar Documents

Publication Publication Date Title
IL248350A0 (en) Fast-acting insulin preparations
PT3233108T (pt) Composições de insulina de atuação rápida
ZA201800511B (en) Rapid-acting insulin compositions
GB201501859D0 (en) Composition
GB201410905D0 (en) Composition
IL251703A0 (en) A pharmaceutical preparation with improved stability
SG11201704735WA (en) Composition
ZA201704464B (en) Composition
GB201403017D0 (en) Composition
GB201414910D0 (en) Composition
GB201403561D0 (en) Composition
IL270975A (en) Fast-acting insulin preparations
PL3217964T3 (pl) Kompozycja
GB201414555D0 (en) Composition
GB201410493D0 (en) Composition
GB201519442D0 (en) Composition
ZA201606127B (en) Composition
GB201420628D0 (en) Composition
GB201415483D0 (en) Composition
GB201404390D0 (en) Composition
GB201402648D0 (en) Composition
IL250781A0 (en) preparation
GB201503484D0 (en) Composition
GB201502355D0 (en) Composition
GB201421660D0 (en) Composition